Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.
Dapagliflozin
Body Weight+4
+ Nutrition Disorders
+ Nutritional and Metabolic Diseases
Treatment Study
Summary
Study start date: October 28, 2021
Actual date on which the first participant was enrolled.This study is focused on understanding how a medication called dapagliflozin can help overweight women lose weight, especially when they consume different amounts of carbohydrates in their diets. Around 36 women who are overweight will participate in this trial. Initially, they will follow their usual eating habits for four weeks. If their weight doesn't change much during this period, they will continue into the next phase. The goal is to explore how effective dapagliflozin is at promoting weight loss, potentially offering a new way to manage weight, especially for those struggling with obesity. Participants will take dapagliflozin tablets by mouth once a day for 12 weeks while continuing their normal diet. To monitor progress, they will keep a detailed food diary three times a week. Researchers will collect various health indicators, including blood pressure, blood sugar levels, body measurements, and urine samples, to see how the medication affects their weight and overall health. Additionally, the study will examine the participants' gut bacteria by analyzing stool samples. Participants are divided into two groups based on their carbohydrate intake to see if the amount of carbohydrates they eat influences the effectiveness of the treatment. This study will help understand any potential side effects or benefits of using dapagliflozin for weight loss in women.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.36 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.From 18 to 45 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 2 locations
Zhujiang Hospital of Southern Medical University
Guangzhou, ChinaOpen Zhujiang Hospital of Southern Medical University in Google MapsZhujiang Hospital
Guangzhou, China